Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $73.00.

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. HC Wainwright lifted their target price on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Chardan Capital increased their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 16,250 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the sale, the chief operating officer owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This trade represents a 9.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 510,836 shares of company stock worth $33,603,060. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Marex Group plc purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $576,000. Nordea Investment Management AB raised its stake in shares of Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company’s stock valued at $12,661,000 after acquiring an additional 158,937 shares in the last quarter. Marshall Wace LLP boosted its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. HBK Sorce Advisory LLC acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $2,823,000. Finally, Moody Lynn & Lieberson LLC purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $213,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Up 2.3%

Shares of ARWR stock opened at $65.28 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $76.76. The company’s 50-day moving average price is $60.81 and its 200-day moving average price is $39.19. The stock has a market cap of $8.87 billion, a price-to-earnings ratio of -815.90 and a beta of 1.21.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.